Jakarta, hitclubapk3 Indonesia
—
BPI Chief Operating Officer (COO).
Danantara
Indonesia’s Dony Oskaria opens his voice regarding news of layoffs (
Layoffs
) mass towards 413 employees of PT
Indofarma
Tbk (INAF).
He said that this step was not just layoffs, but part of the company restructuring process that was being carried out by the government and Danantara.
“Actually, it’s not layoffs, but we are offering offers for the restructuring, but we are recruiting some of them back,” said Dony at the Garuda Indonesia Management Building, Tangerang, Thursday (13/11).
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
He added that the entire process was carried out according to regulations and was part of the company’s turnaround efforts.According to him, employees also accepted the decision and some will be re-recruited as HR needs are adjusted.
Dony emphasized that efforts to improve Indofarma must be carried out logically and carefully.Companies do not want to channel funds without clear business direction, especially because it involves the use of state money.
Therefore, efficiency measures and restructuring of the HR structure are part of the ongoing restructuring process.
In the future, Dony said that Indofarma will be under the management of Kimia Farma as part of the consolidation of pharmaceutical BUMN.
Responding to the number of employees remaining only a dozen people after the restructuring, Dony confirmed that the company would again recruit new employees according to operational needs.
He said that former employees who ask to return to join will also be considered during the restructuring process.
“If the company doesn’t have a healthy profile, it’s useless to give money to business people who don’t exist. So we have to
logic
,” he said further.
PT Indofarma Tbk previously reported that it had carried out mass layoffs of 413 employees on September 15 2025, leaving only 3 active employees remaining.
This step is listed in the third quarter 2025 financial report and is said to be part of restructuring for efficiency.
At the end of September, the company opened re-recruitment for 18 employees, bringing the total number of employees to 21 people.HR adjustments are carried out following the limited business model stipulated in the Homologation Decision.
On the same day as the layoffs, the company received a loan of IDR 220 billion from the state-owned pharmaceutical holding company, PT Bio Farma.
These funds are used to support operational cost efficiency.The 12-month term loan with 7 percent interest is accompanied by non-collateral asset collateral in 18 locations.
Indofarma’s problems have been surfacing since 2024. Deputy Minister of BUMN Kartika Wirjoatmodjo explained that the company faced two big problems, namely allegations
fraud
based on the BPKP audit which is now heading for legal proceedings, as well as efforts to save the company.
Special Staff to the Minister of BUMN Arya Sinulingga also said this
fraud
occurred at a subsidiary, PT Indofarma Global Medika, which did not deposit IDR 470 billion in funds to Indofarma.
This problem then disrupted the company’s financial condition, making it difficult to pay salaries, which since last year were borne by Bio Farma.
[Gambas:hitclubapk3 Video]
(sfr/sfr)
